Synthetic Medicinal Chemistry in Chagas’ Disease: Compounds at The Final Stage of “Hit-To-Lead” Phase

Hugo Cerecetto 1,* and Mercedes González 2,*

1 Departamento de Química Orgánica, Facultad de Química, Universidad de la República, Iguá 4225, Montevideo 11400, Uruguay
2 Laboratorio de Química Orgánica, Instituto de Química Biológica-Facultad de Ciencias, Universidad de la República, Iguá 4225, Montevideo 11400, Uruguay

* Authors to whom correspondence should be addressed; E-Mail: hcerecet@fq.edu.uy (H.C.); megonzal@fq.edu.uy (M.G.); Tel.: +59-82-525-0749; Fax: +59-82-525-0749.

Received: 1 February 2010; in revised form: 15 March 2010 / Accepted: 19 March 2010 / Published: 25 March 2010

Abstract: Chagas’ disease, or American trypanosomiasis, has been the most relevant illness produced by protozoa in Latin America. Synthetic medicinal chemistry efforts have provided an extensive number of chemodiverse hits at the “active-to-hit” stage. However, only a more limited number of these have been studied in vivo in models of Chagas’ disease. Herein, we survey some of the candidates able to surpass the “hit-to-lead” stage discussing their limitations or merit to enter in clinical trials in the short term.

Keywords: Chagas’ disease; “hit-to-lead”; drug-likeness

1. Introduction

Despite the fact that Carlos Chagas completely described, near to a century ago [1] the vector, microorganism and clinical signs, American trypanosomiasis, remains the largest parasitic disease burden on the American continent. This illness, also known as Chagas’ disease, is caused by thetrypanosomatid parasite Trypanosoma cruzi (T. cruzi). Like other neglected diseases, it is an important health problem due to inadequate therapy and the lack of an effective vaccine [2]. It has not received much attention by the pharmaceutical industry mainly due to economic considerations. Current clinical treatment of Chagas’ disease relies on two drugs (Figure 1): nifurtimox (Nfx, 3-methyl-4-(5-nitrofurfurylidene-amino)tetrahydro-4H-1,4-thiazine-1,1-dioxide, Lampit®, recently discontinued by
Bayer) and benznidazole (Bnz, N-benzyl-2-(2-nitroimidazolyl)acetamide, Rochagan®, Roche, now produced by LAFEPE, Brazil) discovered empirically more than three decades ago [3]. These drugs are nitroheterocycles that present significant side effects, e.g., Nfx may cause weight loss, skin rash, psychosis, leucopenia, neurotoxicity, peripheral neuropathy, tissue abnormalities, nausea and vomiting; while Bnz may trigger edema, fever, skin rash, peripheral neuropathy, lymphadenopathy, agranulocytosis, thrombocytopenic purpura, articular and muscular pain [4]. The use of these drugs during the acute phase is widely accepted, but their efficacy in the chronic phase is still controversial. Currently, the treatment plan of chronically infected patients is based on the hypothesis that Chagasic cardiomyopathy may be triggered by persistent parasitic infection [5]. Since 2004, the BENEFIT (BENznidazole Evaluation For Interrupting Trypanosomiasis Program) multicenter study involves a randomized, double-blind, placebo-controlled, Bnz clinical trial of 3,000 patients with Chagasic cardiomyopathy from 35 centers of Latin America [6]. Similarly, Nfx, combined with eflornithine, is involved in a multicentre, randomized, open-label, active control phase III trial for treatment of patients with African Trypanosoma brucei gambiense trypanosomiasis [7].

![Chemical structures of clinical used drugs for Chagas’ disease.](image)

Apart from their arguable efficacies in all the disease stages, Nfx y Bnz have showed different efficacies according to both endemic geographical areas and T. cruzi strains [8]. However the most relevant problems are their toxic and genotoxic behaviors that convert them into inappropriate drugs for treatment of any kind of disease [4,9–11]. Given the unsatisfactory pharmaceutical performance of the currently available drugs, new approaches to specific chemotherapy of Chagas’ disease have been advanced in the last three decades. They will be discussed in the following sections focusing in the synthetic medicinal chemistry and on those compounds at the final stage of the “hit-to-lead” phase and with possibilities of entering the clinical phase.

2. Medicinal Chemistry in Chagas’ Disease

Medicinal chemistry, as an interdisciplinary science, has combined all its tools in the discovery of anti-Chagas drugs. Accordingly, efforts have come from biochemistry/molecular biology, computational chemistry, pharmacognosy, pharmacology, drug repositioning, and organic and inorganic chemistry areas. Studies have been done in the different stages of the drug discovery process – hit selection, synthetic development to lead identification, synthetic modifications to lead optimization, and preclinical steps – contributing in a synergistic manner allowing the identification of potential drug candidates.

The information of the complete genome sequences of T. cruzi revealed that its genome contains nearly 10,000 protein-coding genes [12]. This vast amount of new information allows the identification
of targets in an accurate manner [13–17]. From a medicinal chemistry point of view, several potential biological targets for drugs development have been identified, e.g., geranyltransferase type I, farnesyltransferase, farnesy l pyrophosphate synthase, trans-sialidase, cAMP-specific phosphodiesterases, polyamine and trypanothione synthetic pathways, cystein proteases, glucose 6-phosphate dehydrogenase, glyceraldehyde 3-phosphate dehydrogenase, membrane sterols synthetic pathways, or α-hydroxyacid dehydrogenase, but in some cases their validity and druggability as anti-Chagas targets have been placed in doubt.

Computational chemistry has reinforced the generated \textit{T. cruzi} genomic/proteomic information using tools at the hit selection stage, e.g., virtual screening to identify inhibitors of specific parasite biomolecules [18–20], or at the lead optimization step, e.g., developing theoretical models that explain activities [21–23]. Figure 2 shows some examples of selected hits with specific enzymatic inhibitory activities.

Latin America vegetation has supplied a great number of active compounds where the pharmacognosts have identified relevant hits to treat Chagas’ disease. Significant leads have come from Argentine, Brazil, Bolivia, Chile, Paraguay and Peru (Figure 2) [24–29]. However, scarce examples where medicinal chemistry involve in chemical modifications to attempt improvement of the hits’ activities [29–33].

A great deal of work in the pharmacology/toxicology areas has been published by Argentinean, Brazilian and Chilean research teams. Castro’s group in Argentine has worked on the toxicological profile of the current anti-Chagas drugs, Nfx and Bnz [4], while the Chilean team of Morello has driven aspects related to Nfx’s mechanism of action and improvement of its activity by drug-combination [34,35]. On the other hand, the Brazilian group of de Castro has generated relevant information on experimental chemotherapies for Chagas’ disease working \textit{in vitro} but also \textit{in vivo} (Figure 2c, see below, Section 3) [36,37].

Drug repositioning, or drug profiling, is a medicinal chemistry tool that has also been employed in the lead identification stage for Chagas’ disease drugs. The concept of drug profiling, concerning in the research of either discontinued-, off-patent, or another-application-drug for novel indications, has been developed by Urbina from Venezuela [38]. The concept of the biological redundancy has been successfully applied by Urbina employing well-known antifungal drugs as anti-Chagas agents (Figure 2) [39]. The idea that these drugs have undergone extensive toxicological and pharmacokinetic studies support that their indication as anti-Chagas drugs would involve less risk, cost and time than conventional discovery. Based on previous reports on amiodarone’s (14, Figure 2) \textit{in vitro} antifungal activity [40], Urbina found that this drug, used as an antiarrhythmic in Chagasic cardiomyopathy, also possess a synergic anti-\textit{T. cruzi} effect when it is co-administered together with the antifungal posaconazole (compound 11, Figure 2) [41].

Organic and inorganic medicinal chemistry, mainly from academic centers and collaborative networks, has contributed with relevant information from the design, the synthesis, the structural modifications optimizing identified-hits, and the structure-activity relationships. Some of these results and approaches will be discussed in the following section describing those agents emerge from the “active-to-hit” stage.
Figure 2. (a) Chemical structures of selected T. cruzi-enzymatic inhibitors. (b) Chemical structures of selected natural products with anti-T. cruzi activity. (c) Examples of medicinal chemistry based on natural products. (d) Chemical structures of examples of drug-profiling strategy in Chagas’ disease.
2.1. Compounds from the “Active-To-Hit” Phase

The different synthetic medicinal chemistry approaches, at the “active-to-hit” development stage, come mainly from Argentine, Brazil, Germany, Spain, United States, United Kingdom, Uruguay, and Venezuela academic partnerships, in some cases sponsored by WHO and DNDi [42]. The anti-*T. cruzi* *in vitro* studies have been described against three different forms of the parasite, the vectorial epimastigote-, the bloodstream trypomastigote-, and the intracellular amastigote-forms.

Inhibition of enzymes involved in the parasites’ sterol syntheses pathway have been studied by Rodriguez’ team, from Argentine, who have worked on two different chemical systems, thiocyanates and bisphosphonic acids. Compound 15 (Figure 3), a thiocyanate derivative [43–46], a hit with micromolar anti-amastigote activity acts by reduction of the parasite endogenous sterols as result of the inhibition of squalene synthase. The bisphosphonic acids have been developed as inhibitors of *T. cruzi* farnesyl diphosphate synthase (TcFPPS), resulting compound 16 (Figure 3) a molecular prototype with nanomolar anti-amastigote activity and adequate activity against TcFPPS [47,48].

In Brazil, organic chemistry teams have been working on the identification of new molecular hits with capability to inhibit cruzipain, the major cysteine protease from *T. cruzi* [22,23,49,50]. Ferreira’s group has identified the nitrofurazone derivative 17 (Figure 3), initially developed as a synthetic prodrug intermediate, with good anti-*T. cruzi* activity and besides with cruzipain-inhibition property [51]. This compound shows lack of mutagenic property which make it as a good candidate for “hit-to-lead” studies (see below, Section 3.3). Recently, both Leite’s and Lima’s teams have described *N*-acyl-hydrazones, e.g., 18 and 19 (Figure 3), with good *in vitro* activities against the whole parasite, trypomastigote and epimastigote forms, and, according to the theoretical calculations, with potential ability to inhibit the desired enzyme [52,53].

Using cruzipain as the biological target, the group of the Sandler Center (United States) has described the study of an important number of chemical-compound libraries identifying agents with optimal cruzain-inhibition capability [54]. Compound 20, belonging to the vinyl-sulfone family, and its guanidinyl analogue 21, named as K777 and WRR483 [55–57] respectively (Figure 3), have been identified as hits with excellent *in vitro* activity against whole parasite and enzyme that led them to be considered for *in vivo* studies (see below, Section 3). Thiosemicarbazones and 1,2,3-triazoles, e.g., hits 22 and 23 (Figure 3), are other groups of cruzipain inhibitor-pharmacophores studied by these researchers [58,59]. Whereas 23 completely eradicated amastigote *T. cruzi* in cultures thiosemicarbazone 22 had only modest anti-proliferative *T. cruzi* activity.

Additionally, McKerrow’s team have worked on the research and development of *T. cruzi* cytochrome P450 CYP51 (sterol 14α-demethylase) inhibitors finding the hit 24 [60] (Figure 3) that acts as enzymatic inhibitor and also as anti-amastigote agent with low to no toxicity against the studied mammal systems [61]. In the same sense Gelb’s group, from Washington University (United States) has been studying *T. cruzi* CYP51 inhibitors using as chemical template the human protein farnesyltransferase inhibitor tipifarnib. Unexpectedly, this compound with excellent *in vitro* anti-*T. cruzi* activity, was also a *T. cruzi* CYP51 inhibitor [62] allowing the design, syntheses and biological studies of new series of derivatives with activity against this enzyme. The lead compound, 25 (Figure 3), displayed picomolar activity against cultured *T. cruzi*. Interesting hits have been identified from this group being imidazole 26 (Figure 3) submitted to *in vivo* studies (see below, Section 3) [63–65].
The trypanothione-based thiol metabolism has also been used as target for new anti-*T. cruzi* drug identification [66]. In this sense, Dr. Krauth-Siegel’s team, from Heidelberg University (Germany) working together with partnerships from Argentine, France, Switzerland, United Kingdom, United States, and Uruguay, has studied a great number of compounds as trypanothione reductase (TR) inhibitors. The most recent hits described by Krauth-Siegel *et al.* as TR inhibitors are 27–29 (Figure 3) [67–69].

**Figure 3.** Examples of anti-*T. cruzi* products emerging from the synthetic medicinal chemistry, hitherto at the “active-to-hit” development phase.
Figure 3. Cont.

27, $-R_1 = -H$, $-R_2 = -CF_3$, $-R_3 = -Cl$, $-X = -S$
28, $-R_1 = -SF_5$, $-R_2 = -H$, $-R_3 = -F$, $-X = -NH$
Fairlamb’s group, from United Kingdom, sponsored by DNDi and with the participation of partnerships from Australia, Brazil, Canada, Cuba, France, Spain, Switzerland, United States, and Venezuela, has looked forward for new molecular prototypes with ability to inhibit \textit{T. cruzi} TR. Some of the most recent hit compounds are 30–34 (Figure 3). None of them were evaluated against the entire parasite [70–73].

Also from United Kingdom, the Gilbert-group’s chemical efforts working on the anti-\textit{T. cruzi} “active-to-hit” stage should be mentioned. With the participation of partnerships from Australia, Brazil, Canada, Cuba, France, Spain, Switzerland, United States, and Venezuela, Gilbert’s synthetic approaches (e.g., 35–38, Figure 3) have involved inhibitors of \textit{T. cruzi} dihydrofolate reductase [74], azasterols as inhibitors of sterol 24(25)-methyltransferase of \textit{T. cruzi} [75–78], and quinuclidines as inhibitors of squalene synthase of \textit{T. cruzi} [79–81]. The best anti-\textit{T. cruzi} quinuclidines developed by Gilbert \textit{et al.} had an effect on the sterol composition of \textit{Leishmania mexicana} promastigotes (e.g., 37 and 38, Figure 3).

Our group, from Universidad de la República (Uruguay) together with partnerships from Argentine, Brazil, Chile, Italy, Spain, and Venezuela has described different kind of molecular prototypes mainly in the field of the intraparasite-free radical-releasing agents. Some of the most relevant examples are the nitroheterocycles 39–41 [82–85], the N-oxides 42–46 [86–91], and some other interesting heterocycles 47–49 [53,92–94]. Some of them have passed to the “hit-to-lead” phase (see below, Section 3) and others, according to their biological behavior, should advance to this stage in the short to medium-term.

Inorganic synthetic medicinal chemistry has also provided very interesting structural motives as hits for anti-\textit{T. cruzi} drugs. Some of the first examples have came from the Sánchez-Delgado team, from
Venezuela [95,96], however currently Brazilian and Uruguayan groups have been reporting the bulk of results related to inorganic strategies. Different metals have been reacted with chemical entities with antiparasitic/enzymatic inhibitory activity (e.g., 50–52, Figure 3) [97–102] and without specific biological properties (e.g., 53, Figure 3) [103]. These compounds have demonstrated to act by at least two mechanisms [104–106] and some of them have been advanced to in vivo studies (see below, Section 3).

3. Compounds at the Final Stage of “Hit-to-Lead” Phase

A significant number of candidates, from the “active-to-hit” phase, have been submitted to some of the subsequent studies corresponding to the “hit-to-lead” stage. The compounds will be described according to the laboratory and country origins, and aspects related to their drug-like properties—e.g., oral bioavailability, toxicity, mutagenicity—will be analyzed and discussed.

From the Laboratório de Biologia Celular-Instituto Oswaldo Cruz in Brazil, the ergosterol inhibitor compound 54 (as a geometric isomers-mixture, Figure 4) has been studied in a model of infected animals (oral administration of 5 mg/kg b.w. for nine consecutive days, starting on the day of inoculation). This compound produced a consistent suppression of parasitemia combined with full protection against death, 100% of animals’ survival at the end of the assay vs 75% for Bnz-treated animals (at 100 mg/kg b. w.) [107,108]. On the other hand, the diamidines 55 and 56 (Figure 4), active in vitro against the different forms of the parasite, have been studied in vivo using different drug-administration schedules by i.p. route [109–111]. Compound 55 reduced cardiac parasite load and down-modulated the expression of CD8+ T cells in the heart tissues that revert the electrocardiography alterations in acute and chronic infection, leading to an increase in the animals’ survival rates. The best results with diamidine 56 were obtained when the animals received 25 mg/kg b.w. in two intervals, one at the onset and the second at the parasitemia peak, with 100% of animals’ survival, reduction of the cardiac parasitism although only a reduction of 40% in the parasitemia levels. These classes of compounds deserve further investigation, for example pharmacokinetic properties and metabolic stability, based on the adequate anti-T. cruzi in vivo results.

From University of São Paulo, Brazil, Franco’s team has worked in the inorganic medicinal chemistry field evaluating in vivo ruthenium complexes 57, 58 and 59 (Figure 4) [112,113]. Complexes 57 and 58 have been developed as NO-releasing compounds and they probed to be active in vitro against the parasite while in vivo results, i.p. administration of 100 nmol of each compound/kg b.w. daily for 15 consecutive days, showed that they were discrete in both the decreasing of the parasitemia and the animals’ survival rates with decreasing the occurrence of myocarditis (mainly for 58). Complex 59, synthesized using imidazole-nitrogen from Bnz as coordinating atom, has been evaluated in vivo for its toxicity -LD50 using up-and-down test protocol- and for its trypanosomicidal activity in a murine model of acute Chagas’ disease. The antiparasitic studies were done using different dosage’ schedules, e.g., oral and i.p. administration and doses of 100 nmol/kg b.w./day or 385 nmol/kg b.w./day, at least 1,000-fold lower than LD50, for 15 consecutive days or for only three days, the fifth, sixth, and seventh days that precede the parasitaemic peak. Compound 59 proved to protect the infected animals eliminating, according to the micrographs, the hearts and skeletal muscles.
amastigotes. This compound is hydrosoluble but no information about pharmacokinetic properties and metabolic stability was mentioned.

Maldonado’s laboratory, from The University of Texas (United States) has evaluated in vivo the competitive inhibitor of \( \text{T. cruzi lipoamide dehydrogenase} \) \( 60 \) (Figure 4) \([114,115]\). The naphthoquinone was administered 24 hours post-infection -10 mg/kg b.w./ initially one daily i.p. dose for 3 consecutive days, and then 2 more doses, with an interval of 1 day between the doses- observing depletion in parasitemia and animals’ survival up to 60% at 70 days post-infection without apparent signs of toxicity on the uninfected treated animals.

Compounds 20 and 21 (K777 and WRR483, respectively, Figure 3), from Sandler Center (United States) have been analyzed in different models of acute Chagas’ disease, i.e. mice and dogs \([116–118]\). For example, when 20 was administered orally at 50 mg/kg b. w. twice daily for 14 days, to infected dogs the myocardial damage was ameliorated according to serum cardiac troponin I levels and histopathology findings. This compound, which is water soluble, orally bioavailable (20%), neither toxic nor mutagenic \([119]\) and produces an additive effect on parasite killing when used in combination with Bnz \([54]\), has now entered formal preclinical drug development investigations \([54]\).

On the other hand, the vinyl-sulfone 21, an analog of the parent 20 contains a protonizable arginine side-chain that turn it into a better cruzipain inhibitor with activity against the parasite in culture and in an animal model of disease \([54]\).

Compound 26 (Figure 3), from the synthetic medicinal chemistry projects at the University of Washington (United States) had the best in vivo profile when it was administered orally, at 20 or 50 mg/kg b.w. twice per day for 21 days, to mice in an acute model of Chagas’ disease \([65]\). From the pharmacokinetic studies the authors have not observed significant 26 losses out to 5 h, showing its mouse plasma stability. The animals tolerated the drug treatments without apparent side effects however studies of toxicity/mutagenicity were not done. Although the in vivo activity of 26 was lower than that of posaconazole (11, Figure 2), its synthesis is much simpler and its potential cost of goods lower.

Urbina, initially from Instituto Venezolano de Investigaciones Científicas (Venezuela) and now at the University of Cincinnati in the United States, has worked in vivo with well-known ergosterol biosynthesis inhibitors. The antifungals terbinafine, ketoconazole or itraconazole displayed suppressive, but not curative, effects against \( \text{T. cruzi} \) infections in animal models of Chagas’ disease \([120]\). However, triazoles (11–13, Figure 2; 61 and 62, Figure 4) selective inhibitors of fungal and protozoan cytochrome P-450-dependent CYP51 were potent inducing radical parasitological cure in murine models of acute and chronic Chagas’ disease \([121–127]\). The remarkable in vivo antiparasitic activities of some of them result from a combination of their potent and selective intrinsic anti-\( \text{T. cruzi} \) activity and special pharmacokinetic properties (long terminal half-life and large volumes of distribution). For example, posaconazole, 11, has terminal phase half-life of 7–9 h in mice and rats \([128]\). On the other hand, azole 61 has very short half-life in mice but working in a canine model demonstrated curative activity against established infections of the virulent Y strain of \( \text{T. cruzi} \) with very low toxicity but drug resistance was encountered with the Berenice-78 strain \([39]\). Another example of inadequate pharmacokinetic properties in mice was evidenced in the treatment with 62 however these results do not necessarily rule out the potential usefulness of this compound in the treatment of human \( \text{T. cruzi} \) infections since its activity is very high. According to Urbina, triazoles 11
and 62 would be entering into the clinical studies for the treatment of human chronic Chagas disease in the next 12 months [39] (http://www.dndi.org/press-releases/532-eisai-and-dndi-enter-into-a-collaboration.html) moreover taking in account that 11 has been demonstrated to be active in a case of a Chagas’ disease patient compromised with systemic lupus erythematos [129].

**Figure 4.** Examples of anti-*T. cruzi* products emerging from the synthetic medicinal chemistry, hitherto at the “hit-to-lead” development phase.
Another interesting group of compounds that have been studied in vivo by Urbina are the quinuclidine derivatives (e.g., 63 and 64, Figure 4) [130] under development for cholesterol control in humans. The in vivo behavior of compound 63 resulted better than that of 64 producing animal survival rates of 100% and arresting development of parasitemia in the studied murine model of acute disease and in one of the assayed condition, oral treatment at a concentration of 50 mg/kg of b.w./day for 30 consecutive days. The better antiparasitic properties of 63 could be due to its better pharmacokinetic properties, with lower clearance rate in rats than 64 and wide tissue distribution, such as heart, spleen, liver, and intestines [130].

Others examples that should be mentioned for their in vivo relevance are the approaches with products isolated from natural resources. One example comes from Paraguay [25] where canthin-6-one (4, Figure 2), isolated from Zanthoxylum chiloperone as well as the total alkaloids extract from stem bark led parasitological clearance in the experimental conditions, oral or subcutaneous administration at 5mg/kg b.w./day for 2 weeks for the pure product and 50mg/kg b.w./day for 2 weeks for alkaloidal extract. Another example is the sesquiterpene lactone 5 (Figure 2) isolated from Ambrosia tenuifolia Sprengel (Asteraceae) that decreased the parasitemia levels during the experiment and promoted an animals’ survival rate of 100% when it was administered i.p. at 1 mg/kg b.w./day for five consecutive days [26].

Our group at Universidad de la República (Uruguay), in collaboration with Argentinean and Paraguayan teams has assessed nineteen nitroheterocyclic derivatives and ten N-oxide derivatives in different murine models of acute Chagas’ disease [131–136]. In our first approach, we found that each 5-nitrofuran derivative was more in vivo active than the corresponding 5-nitrothiophene analogue, e.g., comparing animals’ survival rates of derivatives 65, 66, 67 and 68 (Figure 5) where they were administered orally during 10 days at 66 mg/kg b.w./day. After that, a series of ten 5-nitrofurans were tested oral and intraperitoneally. Based on the toxicity on murine models investigated with a single administration of 7.5- and 6-fold the therapeutic dose (60 mg/kg b.w.) we selected three among the new derivatives (71, 74, and 75 Figure 5) for testing in vivo anti-T. cruzi activities. A clear relationship between chemical structure and both acute toxicity and in vivo anti-T. cruzi activity was observed, showing that derivatives 65, 67, 69, and 70 promoted higher toxicity, in healthy animals, than derivatives 71–73 and carbazate 74 (Figure 5) was lesser in vivo anti-trypanostigote agent than the semicarbazones 65, 67, and 71, or the amide 75 (Figure 5). Derivative 71 showed an excellent anti-T. cruzi profile for the smooth muscle with adequate profile in the cardiac one. Unfortunately, derivatives 71, 74, and 75 have demonstrated mutagenicity in the Ames test (against S. Typhimurium TA 98) with and without S9 fraction (unpublished data). The 5-nitroindazoles 76 and 77 were selected, for their lack of in vitro unspecific cytotoxicity, to be evaluated in a murine model of acute Chagas’ disease, oral administration at 30 mg/kg b.w./day for 10 days (using Bnz as positive control at 50 mg/kg b.w./day for 10 days). Taking into account that the doses of the tested compounds were very different, 78 mmol/kg b.w./day for 76 and 77 and 192 mmol/kg b.w./day for Bnz, compound 76 showed better in vivo performance than the reference drug, Bnz, in animals’ survival rates and anti-T. cruzi antibody levels. On the other hand, according to parasitemia, animals’ survival rates and antibodies levels compound 77 have an in vivo behavior as good as Bnz. Although further structural modifications and deeper pharmaceutical studies have been done [137,138], this class of compounds deserves further investigation based on the adequate anti-T. cruzi in vivo results. The same experimental protocol has
been used to evaluate the benzimidazole di-N-oxides 78 and 79 (Figure 5) where both compounds were able to rescue mice from death and lowered anti-T. cruzi antibodies levels, especially 78, with only 10 doses in a short-term scheme. Regrettably, compound 78 has demonstrated mutagenicity in the Ames test (against S. Typhimurium TA 98) in absence of metabolic activation (unpublished data). Pharmacokinetic and metabolic-stability studies for compounds 65–77 were not performed.

Figure 5. Examples of anti-T. cruzi products hitherto at the “hit-to-lead” development phase from our laboratory.
Benzofuroxans 80–82 (as geometric isomer mixtures, Figure 5), developed as *T. cruzi* cruzipain inhibitors, have been evaluated in an acute model of Chagas’ disease, oral administration at 60 mg/kg b. w./day for 30 days (6 day treatment, 1 day rest, until 30 doses completed). The mixture of isomers 81 has the best *in vivo* profile among the three tested benzofuroxans and better than Bnz considering the antibody levels. Furthermore, no signs of toxicity were observed in the studied animals, during the treatment, and none of the animals treated with 80–82 died during the treatment while in the control group the survival rate was 75%. Following the same experimental protocol, and as DNDi project, benzofuroxans 83–88 (Figure 5), and the geometric isomers-mixtures, have been studied *in vivo* against different *T. cruzi* strains, e.g., Tulahuen 2 and Colombiana (resistant to Nifurtimox and Benznidazole) strains, and two wild strains, one isolated from the wild reservoir *Didelphis marsupialis* and another one from a Uruguayan patient. The results showed that 83 and the equimolecular mixture 83:84 were able to reduce the parasite loads of animals with fully established *T. cruzi* infections with, in some cases, comparable results to that obtained with both Nfx and Bnz. The results of histological studies indicated that they could be adequate agents in preventing inflammatory infiltrates and tissue damage, particularly in heart of infected animals. The main problem found in these studies was the low compound solubility in the chosen vehicles. Furthermore, according to the acute-toxicity study administration of compound 83, at high doses, did not produce remarkable damage on the animals. As part of the research project supported by DNDi organization others preclinical studies with 83–88, e.g., scaling-up and analytical procedures, *in vitro* metabolism and toxicity, have been performed [139–143]. The mutagenic studies have indicated that benzofuroxans 81, 82 (data not published), 83, 85–88 are mutagenic, in some cases with metabolic activation, like Nfx and Bnz. Derivatives 80, 84 and the equimolecular mixture 83:84 were not-mutagenic in both conditions, unfortunately the isomer 84 is metabolized *in vitro*, and probably *in vivo*, to 83 by hepatocyte microsomal and cytosolic fractions. In deep studies of the metabolites responsible of mutagenicity for derivative 83, one of the main metabolite, 89, and not the other, 90, is mutagenic with S9 activation.

3.1. Drug-like Properties of the anti-*T. cruzi* compounds at the Ending Stage of "Hit-to-Lead" Phase

Adequate drug-like properties of one lead compound allow the researchers to convert it into a successful drug. The term drug-like became used following the work of Lipinski *et al.* [144] who examined the structural properties that affect the physicochemical properties of solubility and permeability and their effect on drug absorption. On the other hand, toxicity studies were traditionally performed during the clinical development phase however it has been a major cause of drug candidate attrition during preclinical and clinical phases. For this reason, the early knowledge about toxicity candidate also allows the researchers to become it in a successful drug.

In this stage of the studies and as a form to anticipate the potential use as drugs, the compounds described here (Section 3) are analyzed in their drug-like properties – e.g., oral bioavailability, genotoxicity, mutagenicity – using *in silico* approaches (Table 1). For compounds’ oral bioavailability Lipinski’ and Veber’ [145] rules are employed, extracting properties from the free websites http://www.molinspiration.com/ and http://www.organic-chemistry.org/prog/peo/, while for the compounds’ potential toxicity/mutagenicity *in silico* classifications are extracted from the website http://www.organic-chemistry.org/prog/peo/ or using the free software Toxtree-v1.60
(http://toxtree.sourceforge.net/). From http://www.organic-chemistry.org/prog/peo/ the descriptors drug-likeness and drug-score are extracted. According to these predictive tools (which represent only some of the free-available ones), one could determine the most promissory candidates that should behave adequately in the next in depth preclinical studies (see colored cells in Table 1): 1) the allylamine 54 and the diamidine 56 with expected both satisfactory oral biodisposal and lack of toxicity; 2) the quinuclidines 63 and 64 with the best values of drug-score and drug-likeness, according to the classification of the Osiris Properties Explorer tools (http://www.organic-chemistry.org/prog/peo/), but with reservations in the potential genotoxic effects (micronucleus assay in rodents) according to Toxtree software; 3) the benzimidazole di-N-oxides 78 and 79 with, except for drug-score values, similar results that quinuclidine derivatives. Unfortunately, the in vitro mutagenicity of compound 78 has been confirmed. Taking in account the behaviors of Nfx and Bnz in these tools, together with the experimental data about their drug-properties, other compounds put on Table 1 could be considered in profound preclinical trials, e.g., 4, 13, 55, 61, 67, 68, 69, 76, 77, 83, 84, 87, and 88.

Table 1. Drug-like properties of compounds described in Section 3.

| Compd. | Meets Lipinski's rule | Meets Veber’s rule | Drug-likeness\(^1\) | Drug-score\(^1\) | Toxic effects\(^1\) | Alerts for mn\(^2\) | Carcinogenic - mutagenic effects\(^2\) |
|--------|-----------------------|-------------------|---------------------|-------------------|-------------------|------------------|----------------------------------|
| 4      | y (0)\(^3\)           | y (0)\(^3\)       | -0.98\(^4\)         | 0.54\(^5\)       | n\(^6\)           | I\(^7\)           | A\(^8\)                          |
| 5      | y (0)                 | y (0)             | -10.47              | 0.22              | y (m,i)           | I                | C                               |
| 11     | n (2)                 | n (1)             | 4.51                | 0.05              | y (m,t,i)         | I                | C                               |
| 12     | y (1)                 | n (1)             | -9.42               | 0.16              | y (i,r)           | I                | C                               |
| 13     | y (1)                 | y (0)             | -4.34               | 0.13              | y (i,r)           | I                | C                               |
| 20     | y (1)                 | n (1)             | 0.48                | 0.29              | y (i)             | I                | C                               |
| 21     | n (3)                 | n (2)             | 1.21                | 0.41              | y (i)             | I                | C                               |
| 26     | n (2)                 | y (0)             | -2.68               | 0.05              | y (m,t,i)         | I                | A,F                             |
| 54\(^10\) | y (1)             | y (0)             | -3.08               | 0.14              | n                 | II               | C                               |
| 55     | y (1)                 | y (0)             | 0.38                | 0.28              | n                 | II               | C,D                             |
| 56     | y (1)                 | y (0)             | -2.61               | 0.29              | n                 | II               | C                               |
| 57     | y (1)                 | n (1)             | -9                  | -                 | -                 | I                | C                               |
| 58     | y (1)                 | n (1)             | -                   | -                 | -                 | I                | C                               |
| 59     | n (2)                 | n (1)             | -                   | -                 | -                 | I                | C                               |
| 60     | y (1)                 | y (0)             | -1.38               | 0.23              | y (r)             | I                | A                               |
| 61     | y (0)                 | y (0)             | 3.41                | 0.51              | y (r)             | I                | C                               |
| 62     | y (0)                 | y (0)             | -7.2                | 0.08              | y (m,t,i,r)       | I                | C                               |
| 63     | y (0)                 | y (0)             | 2.76                | 0.64              | n                 | I                | C                               |
| 64     | y (0)                 | y (0)             | 1.43                | 0.53              | n                 | I                | C                               |
| 65     | y (0)                 | y (0)             | 1.01                | 0.55              | y (m)             | I                | A                               |
| 66     | y (0)\(^3\)          | y (0)\(^3\)       | -2.61\(^4\)         | 0.33\(^5\)       | y (m)\(^6\)       | I\(^7\)          | A\(^8\)                        |
|        |                      |                   | 1.57                | 0.81              | n                 | I                | A                               |
| 67     | y (0)                 | y (0)             |                     |                   |                   | I                | A                               |
### Table 1. Cont.

| Compd. | Meets Lipinski’s rule | Meets Veber’s rule | Drug-likeness | Drug-score | Toxic effects | Alerts for mn | Carcinogenic - mutagenic effects |
|--------|-----------------------|--------------------|---------------|------------|--------------|---------------|-------------------------------|
| 68     | y (0)                 | y (0)              | -2.09         | 0.49       | n            | I             | A                             |
| 69     | y (0)                 | y (0)              | -15.56        | 0.19       | y (i)        | I             | A                             |
| 70     | y (0)                 | n (1)              | -23.57        | 0.21       | y (i)        | I             | A                             |
| 71     | y (0)                 | y (0)              | -17.57        | 0.11       | y (m,i)      | I             | A                             |
| 72     | y (0)                 | y (0)              | -8.91         | 0.17       | y (m,i)      | I             | A                             |
| 73     | y (0)                 | y (0)              | -17.57        | 0.11       | y (m,i)      | I             | A                             |
| 74     | y (0)                 | n (1)              | -25.58        | 0.11       | y (m,i)      | I             | A                             |
| 75     | y (0)                 | y (0)              | -13.95        | 0.23       | y (m)        | I             | A                             |
| 76     | y (0)                 | y (0)              | -5.98         | 0.43       | n            | I             | A                             |
| 77     | y (0)                 | y (0)              | -9.05         | 0.40       | n            | I             | A                             |
| 78     | y (0)                 | y (0)              | -2.43         | 0.53       | n            | I             | C                             |
| 79     | y (0)                 | y (0)              | -8.82         | 0.49       | n            | I             | C                             |
| 80     | y (0)                 | y (0)              | -3.64         | 0.24       | n            | I             | A                             |
| 81     | y (0)                 | y (0)              | -5.44         | 0.32       | n            | I             | A                             |
| 82     | y (0)                 | y (0)              | -12.28        | 0.25       | y (i)        | I             | A                             |
| 83     | y (0)                 | y (0)              | -3.53         | 0.28       | n            | I             | A                             |
| 84     | y (0)                 | y (0)              | -3.53         | 0.28       | n            | I             | A                             |
| 85     | y (1)                 | y (0)              | -0.95         | 0.22       | y (m)        | I             | A/B                           |
| 86     | y (1)                 | y (0)              | -0.95         | 0.22       | y (m)        | I             | A/B                           |
| 87     | y (0)                 | y (0)              | -1.48         | 0.27       | n            | I             | A                             |
| 88     | y (0)                 | y (0)              | -1.48         | 0.27       | n            | I             | A                             |
| Nfx    | y (0)                 | y (0)              | 0.65          | 0.16       | n (m,t,r)    | I             | A                             |
| Bnz    | y (0)                 | y (0)              | -3.32         | 0.18       | n (m,r)      | I             | A                             |

1 From http://www.organic-chemistry.org/prog/peo/. 2 According to Toxtree-v1.60 software [146,147]. mn: micronucleus. 3 y: adjust; n: no adjust; in parenthesis number of violations of the rule. 4 Positive value is for a compound that contains predominantly fragments frequent in commercial drugs. 5 The drug score combines drug-likeness, cLogP, logS, MW and toxicity risks. 6 y: toxic effect, mutagenic (m), tumorogenic (t), irritant (i); reproductive effective (r); n: non toxic effects. 7 Structure alerts for the in vivo micronucleus assay in rodents. I: At least one positive structural alert for the micronucleus assay; II: No alerts for the micronucleus assay. 8 Benigni/Bossa rulebase for mutagenicity and carcinogenicity; A: structural alert for genotoxic carcinogenicity; B: structural alert for nonnongenic carcinogenicity; C: no alerts for carcinogenic activity; D: potential S. typhimurium TA100 mutagen based on QSAR; E: unlikely to be a S. typhimurium TA100 mutagen based on QSAR; F: potential carcinogen based on QSAR; G: unlikely to be a carcinogen based on QSAR; H: for a better assessment a QSAR calculation could be applied; J: error when applying the decision tree. 9 “-”: no result. 10 Study as E-isomer. The color of the cell refers to: green, good result; yellow, intermediate; rose, bad result.
3.2. Scale-Up Information of the anti-T. cruzi Compounds at the Ending Stage of “Hit-to-Lead” Phase

Another relevant aspect in the preclinical and clinical stage, and in the pharmaceutical production, is the adequate product scalability in the synthesis or extraction. This means both environmental friendly processes and Good Manufacturing Practices (GMP). In the case of Chagas’ disease, a neglected disease of deprived countries, low costs are also essential.

Only for some of the compounds described here (Section 3) the scale-up procedures have been assayed [54,139] besides the antifungal azoles (11–13, 61, and 62) and the cholesterol-control quinuclidines (63 and 64). On the other hand, these compounds with at least one chiral center, together with 20 and 21, or those with geometric isomers, like 54, 57–59, 71–75, and 80–88, have the additional complexity that specific and well-controlled synthetic procedures must be used because only one of the stereoisomers is the responsible for the activity. In this sense, compound 26 is a good alternative, as it is less expensive to produce as claimed by the researchers, than other T. cruzi CYP51 inhibitors [65].

3.3. Candidates to be Submitted at the “Hit-to-Lead” Phase in the Short to Medium-Term

We want to highlight three compounds whose lack of mutagenicity makes them potential candidates that should be submitted to the “hit-to-lead” phase in the short to medium-term. One of them is 5-nitrofuran 17 (Figure 3 and Figure 6), that has been developed by Ferreira, from Universidade do São Paulo (Brazil), as nitrofurazone prodrug intermediate. Besides its excellent anti-T. cruzi activity it demonstrated lower mutagenic effects than the parent compound nitrofuran [148,149]. The other two compounds are the 5-nitrofuran and 5-nitrothiophene, 91 and 92, respectively (Figure 6), developed in our group [85,150]. In addition to their excellent in vitro anti-T. cruzi activities they were non-mutagenic in both conditions with and without metabolic activation (unpublished data).

Figure 6. 5-Nitrofuran and 5-nitrothiophene derivatives without mutagenic effects (Ames test).

4. Conclusions

In conclusion, there is currently a number of candidates for preclinical and clinical trials for the identification of new effective anti-Chagas’ drugs, guaranteeing tolerability, safety profile, and selectivity. Another relevant aspect that should be studied and considered is the cost of production of the new agents that could guarantee patient access to these drugs.

Acknowledgements

The authors thank RIDIMEDCHAG-CYTED for financial support.
References and Notes

1. Chagas, C. Nova entidade morbida do homen. Resumo geral dos estudos etiológicos e clínicos. *Mem. Inst. Oswaldo Cruz* **1911**, *3*, 219–275.

2. Tekiel, V.; Alba-Soto, C.D.; González Cappa, S.M.; Postan, M.; Sánchez, D.O. Identification of novel vaccine candidates for Chagas’ disease by immunization with sequential fractions of a trypomastigote cDNA expression library. *Vaccine* **2009**, *27*, 1323–1332.

3. Cerecetto, H.; González, M. Chemotherapy of Chagas' disease: Status and new developments. *Curr. Top. Med. Chem.* **2002**, *2*, 1187–213.

4. Castro, J.A.; Montalto de Mecca, M.; Bartel, L.C. Toxic side effects of drugs used to treat Chagas’ disease (American Trypanosomiasis). *Hum. Exp. Toxicol.* **2006**, *25*, 471–479.

5. Jannin, J.; Villa, L. An overview of Chagas disease treatment. *Mem. Inst. Oswaldo Cruz* **2007**, *102*, 95–97.

6. Marin-Neto, J.A.; Rassi, A.; Morillo, C.A.; Avezum, A.; Connolly, S.J.; Sosa-Estani, S.; Rosas, F.; Yusuf, S. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). *Am. Heart J.* **2008**, *156*, 37–43.

7. Priotto, G.; Kasparian, S.; Mutombo, W.; Ngouama, D.; Ghorashian, S.; Arnold, U.; Ghabri, S.; Baudin, E.; Buard, V.; Kazadi-Kyanza, S.; Ilunga, M.; Mutangala, W.; Pohlig, G.; Schmid, C.; Karunakara, U.; Torreele, E.; Kande, V. Nifurtimox-eflornithine combination therapy for second-stage African *Trypanosoma brucei gambiense* trypanosomiasis: A multicentre, randomised, phase III, non-inferiority trial. *Lancet* **2009**, *374*, 56–64.

8. Murta, S.M.; Gazzinelli, R.T.; Brener, Z.; Romanha, A.J. Molecular characterization of susceptible and naturally resistant strains of *Trypanosoma cruzi* to benznidazole and nifurtimox. *Mol. Biochem. Parasitol.* **1998**, *93*, 203–214.

9. Nagel, R. Genotoxicity studies with two antichagasic drugs. *Mutat. Res.* **1987**, *191*, 17–20.

10. de Castro, C.R.; Montalto de Mecca, M.; Fanelli, S.L.; de Ferreyra, E.C.; Diaz, E.G.; Castro, J.A. Benznidazole-induced ultrastructural and biochemical alterations in rat esophagus. *Toxicology* **2003**, *191*, 189–198.

11. Bartel, L.C.; Montalto de Mecca, M.; Fanelli, S.L.; Rodriguez de Castro, C.; Diaz, E.G.; Castro, J.A. Early nifurtimox-induced biochemical and ultrastructural alterations in rat heart. *Hum. Exp. Toxicology* **2007**, *26*, 781–788.

12. El-Sayed, N.M.; Myler, P.J.; Bartholomeu, D.C.; Nilsson, D.; Aggarwal, G.; Tran, A.N.; Ghedin, E.; Worthey, E.A.; Delcher, A.L.; Blandin, G.; *et al.* Comparative genomics of trypanosomatid parasitic protozoa. *Science* **2005**, *309*, 404–409.

13. Burleigh, B.A. Probing *Trypanosoma cruzi* biology with DNA microarrays. *Parasitology* **2004**, *128*, S3–S10.

14. Heby, O.; Persson, L.; Rentala, M. Targeting the polyamine biosynthetic enzymes: A promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis. *Amino Acids* **2007**, *33*, 359–366.

15. Datta, A.K.; Datta, R.; Sen, B. Antiparasitic chemotherapy: Tinkering with the purine salvage pathway. *Adv. Exp. Med. Biol.* **2008**, *625*, 116–132.
16. Niemirowicz, G.; Fernández, D.; Solà, M.; Cazzulo, J.J.; Avilés, F.X.; Gomis-Rüth, F.X. The molecular analysis of *Trypanosoma cruzi* metallocarboxypeptidase 1 provides insight into fold and substrate specificity. *Mol. Microbiol.* **2008**, *70*, 853–866.

17. Alvarez, V.E.; Kosec, G.; Sant’Anna, C.; Turk, V.; Cazzulo, J.J.; Turk, B. Blocking autophagy to prevent parasite differentiation: A possible new strategy for fighting parasitic infections? *Autophagy* **2008**, *4*, 361–363.

18. Meiering, S.; Inhoff, O.; Mies, J.; Vincek, A.; Garcia, G.; Kramer, B.; Dormeyer, M.; Krauth-Siegel, R.L. Inhibitors of *Trypanosoma cruzi* trypanothione reductase revealed by virtual screening and parallel synthesis. *J. Med. Chem.* **2005**, *48*, 4793–4802.

19. Neres, J.; Brewer, M.L.; Ratier, L.; Botti, H.; Buschiazzo, A.; Edwards, P.N.; Mortenson, P.N.; Charlton, M.H.; Alzari, P.M.; Frasch, A.C.; Bryce, R.A.; Douglas, K.T. Discovery of novel inhibitors of *Trypanosoma cruzi* trans-sialidase from in silico screening. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 589–596.

20. Freitas, R.F.; Prokopczyk, I.M.; Zottis, A.; Oliva, G.; Andricopulo, A.D.; Trevisan, M.T.; Vilegas, W.; Silva, M.G.; Montanari, C.A. Discovery of novel *Trypanosoma cruzi* glyceraldehyde-3-phosphate dehydrogenase inhibitors. *Bioorg. Med. Chem. Chem.* **2009**, *17*, 2476–2482.

21. Menezes, I.R.; Lopes, J.C.; Montanari, C.A.; Oliva, G.; Pavão, F.; Castilho, M.S.; Vieira, P.C.; Pupo, M.T. 3D QSAR studies on binding affinities of coumarin natural products for glycosomal GAPDH of *Trypanosoma cruzi*. *J. Comput. Aided Mol. Des.* **2003**, *17*, 277–290.

22. Guido, R.V.; Trossini, G.H.; Castilho, M.S.; Oliva, G.; Ferreira, E.I.; Andricopulo, A.D. Structure-activity relationships for a class of selective inhibitors of the major cysteine protease from *Trypanosoma cruzi*. *J. Enzyme Inhib. Med. Chem.* **2008**, *23*, 964–973.

23. Trossini, G.H.; Guido, R.V.; Oliva, G.; Ferreira, E.I.; Andricopulo, A.D. Quantitative structure-activity relationships for a series of inhibitors of cruzain from *Trypanosoma cruzi*: Molecular modeling, CoMFA and CoMSIA studies. *J. Mol. Graph. Model* **2009**, *28*, 3–11.

24. Saeidnia, S.; Gohari, A.R.; Ito, M.; Kiuchi, F.; Honda, G. Bioactive constituents from *Dracocephalum subcapitatum* (O. Kuntze) Lipsky. *Z. Naturforsch C.* **2005**, *60*, 22–24.

25. Ferreira, M.E.; Nakayama, H.; de Arias, A.R.; Schinini, A.; de Bilbao, N.V.; Serna, E.; Lagoute, D.; Soriano-Ahatón, F.; Poupon, E.; Hocquelemiller, R.; Fournet, A. Effects of canthin-6-one alkaloids from *Zanthoxylum chiloperone* on *Trypanosoma cruzi*-infected mice. *J. Ethnopharmacol.* **2007**, *109*, 258–263.

26. Sülken, V.P.; Cazorla, S.I.; Frank, F.M.; Redko, F.C.; Anesini, C.A.; Coussio, J.D.; Malchiodi, E.L.; Martino, V.S.; Muschietti, L.V. Trypanocidal and leishmanicidal activities of flavonoids from Argentine medicinal plants. *Am. J. Trop. Med. Hyg.* **2007**, *77*, 654–659.

27. Sülken, V.P.; Frank, F.M.; Cazorla, S.I.; Anesini, C.A.; Malchiodi, E.L.; Freixa, B.; Vila, R.; Muschietti, L.V.; Martino, V.S. Trypanocidal and leishmanicidal activities of sesquiterpene lactones from *Ambrosia tenuifolia* Sprengel (Asteraceae). *Antimicrob. Agents Chemother.* **2008**, *52*, 2415–2419.

28. Aponte, J.C.; Vaisberg, A.J.; Rojas, R.; Sauvain, M.; Lewis, W.H.; Lamas, G., Sarasara, C.; Gilman, R.H.; Hammond, G.B. A multipronged approach to the study of Peruvian ethnomedicinal plants: A legacy of the ICBG-Peru project. *J. Nat. Prod.* **2009**, *72*, 524–526.
29. de Castro, S.L.; Pinto, M.C.F.R.; Pinto, A.V. Screening of natural and synthetic drugs against Trypanosoma cruzi. 1 - Establishing a structure/activity relationship. *Microbios* **1994**, *78*, 83–90.

30. Pinto, A.V.; Neves Pinto, C.; Pinto, M.C.F.R.; Santa Rita, R.M.; Pezzella, C.; de Castro, S.L. Trypanocidal activity of synthetic heterocyclic derivatives from active quinones from *Tabebuia* sp. *Arzneim-Forsch* **1997**, *47*, 74–79.

31. Moura, K.C.G.; Emery, F.S.; Neves-Pinto, C.; Pinto, M.C.F.R.; Santa Rita, R.M.; Pezzella, C.; de Castro, S.L. Trypanocidal activity of synthetic heterocyclic derivatives from active quinones from *Tabebuia* sp. *Arzneim-Forsch* **1997**, *47*, 74–79.

32. Graebin, C.S.; Madeira, M.F.; Yokoyama-Yasunaka, J.K.U.; Miguel, D.C.; Uliana, S.R.B.; Benitez, D.; Cerecetto, H.; González, M.; Gomes da Rosa, R.; Eifler-Lima, V.L. Synthesis and *in vitro* activity of limonene derivatives against *Leishmania* and *Trypanosoma*. *Eur. J. Med. Chem.* **2010**, *45*, 1524–1528.

33. Álvarez, G.; Gerpe, A.; Benitez, D.; Garibotto, F.; Zacchino, S.; Graebin, C.S.; Gomes da Rosa, R.; Eifler-Lima, V.L.; González, M.; Cerecetto, H. New limonene-hybrid derivatives with anti-*T. cruzi* activity. *Lett. Drug Des. Disc.* **2010**, *7*, in press.

34. Faúndez, M.; López-Muñoz, R.; Torres, G.; Morello, A.; Ferreira, J.; Kemmerling, U.; Orellana, M.; Maya, J.D. Buthionine sulfoximine has anti-*Trypanosoma cruzi* activity in a murine model of acute Chagas’ disease and enhances the efficacy of nifurtimox. *Antimicrob. Agents Chemother.* **2008**, *52*, 1837–1839.

35. López-Muñoz, R.; Faúndez, M.; Klein, S.; Escanilla, S.; Torres, G.; Lee-Liu, D.; Ferreira, J.; Kemmerling, U.; Orellana, M.; Maya, J.D. *Trypanosoma cruzi*: *In vitro* effect of aspirin with nifurtimox and benznidazole. *Exp. Parasitol.* **2010**, *124*, 167–171.

36. Soeiro, M.N.C.; Dantas, A.P.; Daliry, A.; da Silva, C.F.; Batista, D.G.J.; de Souza, E.M.; Oliveira, G.M.; Salomão, K.; Batista, M.M.; Pacheco, M.G.O.; Bernardino da Silva, P.; Santa-Rita, R.M.; Menna Barreto, R.F.S.; Boykin, D.W.; de Castro, S.L. Experimental chemotherapy for Chagas disease: 15 years of research contributions from *in vivo* and *in vitro* studies. *Mem.Inst. Oswaldo Cruz* **2009**, *104*, 301–310.

37. Menna Barreto, R.F.; Salomão, K.; Dantas, A.P.; Santa-Rita, R.M.; Soares, M.J.; Barbosa, H.S.; de Castro, S.L. Different cell death pathways induced by drugs in *Trypanosoma cruzi*: An ultrastructural study. *Micron* **2009**, *40*, 157–168.

38. Urbina, J.A.; Lira, R.; Visbal, G.; Bartrolí, J. *In vitro* antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite *Trypanosoma (Schizotrypanum) cruzi*. *Antimicrob. Agents Chemother.* **2000**, *44*, 2498–2502.

39. Urbina, J.A. Ergosterol biosynthesis and drug development for Chagas disease. *Mem. In st. Oswaldo Cruz* **2009**, *104*, 311–318.

40. Courchesne, W.E. Characterization of a novel, broad-based fungicidal activity for the antiarrhythmic drug amiodarone. *J. Pharmacol. Exp. Ther.* **2002**, *300*, 195–199.

41. Benaim, G.; Sanders, J.M.; Garcia-Marchan, Y.; Colina, C.; Lira, R.; Caldera, A.R.; Payares, G.; Sanoja, C.; Burgos, J.M.; Leon-Rossell, A.; Concepcion, J.L.; Schijman, A.G.; Levin, M.; Oldfield, E.; Urbina, J.A. Amiodarone has intrinsic anti-*Trypanosoma cruzi* activity and acts synergistically with Posaconazole. *J. Med. Chem.* **2006**, *49*, 892–899.
42. http://apps.who.int/tdr/svc/grants or http://www.dndi.org/, accessed on 24 March 2010.
43. Elhalem, E.; Bailey, B.N.; Docampo, R.; Ujváry, I.; Szajnman, S.H.; Rodriguez, J.B. Design, synthesis, and biological evaluation of arylxyethyl thiocyanate derivatives against Trypanosoma cruzi. J. Med. Chem. 2002, 45, 3984–3999.
44. Szajnman, S.H.; Yan, W.; Bailey, B.N.; Docampo, R.; Elhalem, E.; Rodriguez, J.B. Design and synthesis of arylxyethyl thiocyanate derivatives as potent inhibitors of Trypanosoma cruzi proliferation. J. Med. Chem. 2000, 43, 1826–1840.
45. Urbina, J.A.; Concepcion, J.L.; Montalvetti, A.; Rodriguez, J.B.; Docampo, R. Mechanism of action of 4-phenoxyphenoxyethyl thiocyanate (WC-9) against Trypanosoma cruzi, the causative agent of Chagas' disease. Antimicrob. Agents Chemother. 2003, 47, 2047–2050.
46. Liñares, G.G.; Gismondi, S.; Codesido, N.O.; Moreno, S.N.; Docampo, R.; Rodriguez, J.B. Fluorine-containing arylxyethyl thiocyanate derivatives are potent inhibitors of Trypanosoma cruzi and Toxoplasma gondii proliferation. Bioorg. Med. Chem. Lett. 2007, 17, 5068–5071.
47. Szajnman, S.H.; Ravaschino, E.L.; Docampo, R.; Rodriguez, J.B. Synthesis and biological evaluation of 1-amino-1,1-bisphosphonates derived from fatty acids against Trypanosoma cruzi targeting farnesyl pyrophosphate synthase. Bioorg. Med. Chem. Lett. 2005, 15, 4685–4690.
48. Szajnman, S.H.; García Liñares, G.E.; Li, Z.H.; Jiang, C.; Galizzi, M.; Bontempi, E.J.; Ferella, M.; Moreno, S.N.; Docampo, R.; Rodriguez, J.B. Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase. Bioorg. Med. Chem. 2008, 16, 3283–3290.
49. Lima Leite, A.C.; Souza de Lima, R.; de M. Moreira, D.R.; de O. Cardoso, M.V.; Gouveia de Brito, A.C.; Farias dos Santos, L.M.; Zaldini Hernandes, M.; Costa Kiperstok, A.; Santana de Lima, R.; Soares, M.B.P. Synthesis, docking, and in vitro activity of thiosemicarbazones, aminoacyl-thiosemicarbazides and acyl-thiazolidones against Trypanosoma cruzi. Bioorg. Med. Chem. 2006, 14, 3749–3757.
50. Leite, A.C.L.; Moreira, D.R.M.; Cardoso, M.V.O.; Hernandes, M.Z.; Pereira, V.R.A.; Silva, R.O.; Kiperstok, A.C.; Lima, M.S.; Soares, M.B.P. Synthesis, cruzain docking, and in vitro studies of aryl-4-oxothiazolylhydrazones as anti-Trypanosoma cruzi agents. Bioorg. Med. Chem. 2009, 17, 6682–6691.
51. Romeiro, N.C.; Aguirre, G.; Hernández, P.; González, M.; Cerecetto, H.; Aldana, I.; Pérez-Silanes, S.; Monge, A.; Barreiro, E.J.; Lima, L.M. Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorg. Med. Chem. 2009, 17, 641–652.
54. McKerrow, J.H.; Doyle, P.S.; Engel, J.C.; Podust, L.M.; Robertson, S.A.; Ferreira, R.; Saxton, T.; Arkin, M.; Kerr, I.D.; Brinen, L.S.; Craik, C.S. Two approaches to discovering and developing new drugs for Chagas disease. *Mem. Inst. Oswaldo Cruz* 2009, 104, 263–269.

55. Roush, W.R.; Gwaltney, S.L.; Cheng, J.; Scheidt, K.A.; McKerrow, J.H.; Hansell, E. Vinyl sulfonate esters and vinyl sulfonamides: Potent, irreversible inhibitors of cysteine proteases. *J. Am. Chem. Soc.* 1998, 120, 10994–10995.

56. Roush, W.R.; Cheng, J.; Knapp-Reed, B.; Alvarez-Hernandez, A.; McKerrow, J.H.; Hansell, E.; Engel, J.C. Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain. *Bioorg. Med. Chem. Lett.* 2001, 11, 2759–2762.

57. Meléndez-López, S.G.; Herdman, S.; Hirata, K.; Choi, M.H.; Choe, Y.; Craik, C.; Caffrey, C.R.; Hansel, E.; Chávez-Munguía, B.; Chen, Y.T.; Roush, W.R.; McKerrow, J.; Eckmann, L.; Guo, J.; Stanley, S.L.; Reed, S.L. Use of recombinant *Entamoeba histolytica* cysteine proteinase to identify a potent inhibitor of amebic invasion in a human colonic model. *Eukaryot. Cell* 2007, 6, 1130–1136.

58. Fujii, N.; Mallari, J.P.; Hansell, E.J.; Mackey, Z.; Doyle, P.; Zhou, Y.M.; Gut, J.; Rosenthal, P.J.; McKerrow, J.H.; Guy, R.K. Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain. *Bioorg. Med. Chem. Lett.* 2005, 15, 121–123.

59. Brak, K.; Doyle, P.S.; McKerrow, J.H.; Ellman, J.A. Identification of a new class of nonpeptidic inhibitors of cruzain. *J Am Chem Soc.* 2008, 130, 6404–6410.

60. Podust, L.M.; von Kries, J.P.; Nasser Eddine, A.; Kim, Y.; Yermalitskaya, L.V.; Kuehne, R.; Ouellet, H.; Warrier, T.; Alteköster, M.; Lee, J.S.; Rademann, J.; Oschkinat, H.; Kaufmann, S.H.E.; Waterman, M.R. Small molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography. *Antimicrob. Agents Chemother.* 2007, 51, 3915–3923.

61. Chen, C.K.; Doyle, P.S.; Yermalitskaya, L.V.; Mackey, Z.B.; Ang, K.K.H.; McKerrow, J.H.; Podust, L.M. *Trypanosoma cruzi* CYP51 inhibitor derived from a *Mycobacterium tuberculosis* screen Hit. *PLoS Negl. Trop. Dis.* 2009, 3, e372.

62. Hucke, O.; Gelb, M.H.; Verlinde, C.L.M.J.; Buckner, F.S. The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. *J. Med. Chem.* 2005, 48, 5415–5418.

63. Kraus, J.M.; Verlinde, C.L.; Karimi, M.; Lepesheva, G.I.; Gelb, M.H.; Buckner, F.S. Rational modification of a candidate cancer drug for use against Chagas disease. *J. Med. Chem.* 2009, 52, 1639–1647. Erratum in: *J. Med. Chem.* 2009, 52, 4549.

64. Chennamaneni, N.K.; Arif, J.; Buckner, F.S.; Gelb, M.H. Isoquinoline-based analogs of the cancer drug Tipifarnib as a new lead for the development of drugs against Chagas disease. *J. Med. Chem.* 2009, 52, 3703–3715.

65. Suryadevara, P.K.; Olepu, S.; Lockman, J.W.; Okhanda, J.; Karimi, M.; Verlinde, C.L.; Kraus, J.M.; Schoepe, J.; Van Voorhis, W.C.; Hamilton, A.D.; Buckner, F.S.; Gelb, M.H. Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. *J. Med. Chem.* 2009, 52, 3703–3715.

66. Krauth-Siegel, R.L.; Comini, M.A. Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism. *Biochim. Biophys. Acta* 2008, 1780, 1236–1248.
67. Stump, B.; Eberle, C.; Kaiser, M.; Brun, R.; Krauth-Siegel, R.L.; Diederich, F. Diaryl sulfide-based inhibitors of trypanothione reductase: Inhibition potency, revised binding mode and antiprotozoal activities. *Org. Biomol. Chem.* **2008**, *6*, 3935–3947.

68. Stump, B.; Eberle, C.; Schweizer, W.B.; Marcel Kaiser, M.; Brun, R.; Krauth-Siegel, R.S.; Diederich, F. Pentafluorosulfanyl as a novel building block for enzyme inhibitors: Trypanothione reductase inhibition and antiprotozoal activities of diarylamines. *Chem. Bio. Chem.* **2009**, *10*, 79–83.

69. Eberle, C.; Burkhard, J.A.; Stump, B.; Kaiser, M.; Brun, R.; Krauth-Siegel, R.S.; Diederich, F. Synthesis, inhibition potency, binding mode, and antiprotozoal activities of fluorescent inhibitors of trypanothione reductase based on mepacrine-conjugated diaryl sulfide scaffolds. *Chem. Med. Chem.* **2009**, *4*, 2034–2044.

70. Martyn, D.C.; Jones, D.C.; Fairlamb, A.H.; Clardy, J. High-throughput screening affords novel and selective trypanothione reductase inhibitors with anti-trypanosomal activity. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 1280–1283.

71. Holloway, G.A.; Baell, J.B.; Fairlamb, A.H.; Novello, P.M.; Parisot, J.P.; Richardson, J.; Watson, K.G.; Street, I.P. Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 1422–1427.

72. Perez-Pineiro, R.; Burgos, A.; Jones, D.C.; Andrew, L.C.; Rodriguez, H.; Suarez, M.; Fairlamb, A.H.; Wishart, D.S. Development of a novel virtual screening cascade protocol to identify potential trypanothione reductase inhibitors. *J. Med. Chem.* **2009**, *52*, 1670–1680.

73. Jones, D.C.; Ariza, A.; Chow, W.H.A.; Oza, S.L.; Fairlamb, A.H. Comparative structural, kinetic and inhibitor studies of *Trypanosoma brucei* trypanothione reductase with *T. cruzi*. *Mol. Biochem. Parasitol.* **2010**, *169*, 12–19.

74. Khabnadideh, S.; Pez, D.; Musso, A.; Brun, R.; Ruiz Pérez, L.M.; González-Pacanowska, D.; Gilbert, I.H. Design, synthesis and evaluation of 2,4-diaminoquinazolines as inhibitors of trypanosomal and leishmanial dihydrofolate reductase. *Bioorg. Med. Chem.* **2005**, *13*, 2637–2649.

75. Orenes Lorente, S.; Jimenez Jimenez, C.; Gros, I.; Yardley, V.; de Luca-Fradley, k.; Croft, S.L.; Urbina, J.A.; Ruiz-Perez, L.M.; Gonzalez Pacanowska, D.; Gilbert, I.H. Preparation of transition-state analogues of sterol 24-methyl transferase as potential anti-parasitics. *J. Med. Chem.* **2006**, *49*, 6094–6103.

76. Gigante, F.; Kaiser, M.; Brun, R.; Gilbert, I.H. SAR studies on azasterols as potential anti-trypanosomal and anti-leishmanial agents. *Bioorg. Med. Chem. Lett.* **2009**, *17*, 5950–5961.

77. Orenes Lorente, S.; Gómez, R.; Jiménez, C.; Cammerer, S.; Yardley, V.; de Luca-Fradley, K.; Croft, S.L.; Ruiz Perez, L.M.; Urbina, J.; Gonzalez Pacanowska, D.; Gilbert, I.H. Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa. *Bioorg. Med. Chem.* **2005**, *13*, 3519–3529.
80. Sealey-Cardona, M.; Cammerer, S.; Jones, S.; Ruiz-Pérez, L.M.; Brun, R.; Gilbert, I.H.; Urbina, J.A.; González-Pacanowska, D. Kinetic characterization of squalene synthase from *Trypanosoma cruzi*: Selective inhibition by quinuclidine derivatives. *Antimicrob. Agents Chemother.* 2007, 51, 2123–2129.

81. Cammerer, S.B.; Jimenez, C.; Jones, S.; Gros, L.; Orenes Lorente, S.; Rodrigues, C.; Rodrigues, J.C.F.; Caldera, A.; Ruiz Perez, L.M.; de Souza, W.; Kaiser, M.; Brun, R.; Urbina, J.A.; Gonzalez Pacanowska, D.; Gilbert, I.H. Quinuclidine derivatives as potential antiparasitics. *Antimicrob. Agents Chemother.* 2007, 51, 4049–4061.

82. Arán, V.J.; Ochoa, C.; Boiani, L.; Buccino, P.; Cerecetto, H.; Gerpe, A.; González, M.; Montero, D.; Nogal, J.J.; Gómez-Barrio, A.; Azqueta, A.; López de Cerán, A.; Piro, O.E.; Castellano, E.E. Synthesis and biological properties of new 5-nitroindazole derivatives. *Bioorg. Med. Chem.* 2005, 13, 3197–3207.

83. Gerpe, A.; Odreman-Nuñez, I.; Draper, P.; Boiani, L.; Urbina, J.A.; González, M.; Cerecetto, H. Heteroallyl-containing 5-nitrofuranes as new anti-*Trypanosoma cruzi* agents with a dual mechanism of action. *Bioorg. Med. Chem.* 2008, 16, 569–577.

84. Rodríguez, J.; Arán, V.J.; Boiani, L.; Olea-Azar, C.; Lavaggi, M.L.; González, M.; Cerecetto, H. Maya, J.D.; Carrasco-Pozo, C.; Cosoy, H.S. New potent 5-nitroindazole derivatives as inhibitors of *Trypanosoma cruzi* growth: Synthesis, biological evaluation, and mechanism of action studies. *Bioorg. Med. Chem.* 2009, 17, 7500–7509.

85. Aguirre, G.; Cerecetto, H.; Di Maio, R.; González, M.; Alfaro, M.E.; Jaso, A.; Zarranz, B.; Ortega, M.A.; Aldana, I.; Monge-Vega, A. Quinoxaline $N,N'$-dioxide derivatives and related compounds as growth inhibitors of *Trypanosoma cruzi*. Structure-activity relationships. *Bioorg. Med. Chem. Lett.* 2004, 14, 3835–3839.

86. Boiani, L.; Aguirre, G.; González, M.; Cerecetto, H.; Idiarte, D.; Cerecetto, H.; Chidichimo, A.; Cazzulo, J.J.; Bertinaria, M.; Guglielmo, S. Furoxan-, alkylnitrate-derivatives and related compounds as antiparasitic agents: Mechanism of action studies. *Bioorg. Med. Chem. Lett.* 2008, 18, 7900–7907.

87. Ancizu, S.; Moreno, E.; Burguete, A.; Pérez-Silanes, S.; Benítez, D.; Villar, R.; Solano, B.; Marín, A.; Aldana, I.; Cerecetto, H.; González, M.; Monge, A. Heterocyclic-2-carboxylic acid (3-cyano-1,4-di-$N$-oxidequinoxalin-2-yl) amide derivatives as hits for the development of neglected disease drugs. *Molecules* 2009, 14, 2256–2272.
91. Castro, D.; Boiani, L.; Benitez, D.; Hernández, P.; Merlino, A.; Gil, C.; Olea-Azar, C.; González, M.; Cerecetto, H.; Porcel, W. Anti-trypanosomatid benzofuroxans and deoxygenated analogues: Synthesis using polymer-supported triphenylphosphine, biological evaluation and mechanism of action studies. *Eur. J. Med. Chem.* 2009, 44, 5055–5065.

92. Lavaggi, M.L.; Aguirre, G.; Boiani, L.; Orelli, L.; García, B.; Cerecetto, H.; González, M. Pyrimido[1,2-a]quinoxaline 6-oxide and phenazine 5,10-dioxide derivatives and related compounds as growth inhibitors of *Trypanosoma cruzi*. *Eur. J. Med. Chem.* 2008, 43, 1737–1741.

93. Caterina, M.C.; Perillo, I.A.; Boiani, L.; Pezaroglo, H.; Cerecetto, H.; González, M.; Salerno, A. Imidazolidines as new anti-*Trypanosoma cruzi* agents: Biological evaluation and structure-activity relationships. *Bioorg. Med. Chem.* 2008, 16, 2226–34.

94. Bollini, M.; Casal, J.J.; Alvarez, D.E.; Boiani, L.; González, M.; Cerecetto, H.; Bruno, A.M. New potent imidazoisoquinolinone derivatives as anti-*Trypanosoma cruzi* agents: Biological evaluation and structure-activity relationships. *Bioorg. Med. Chem.* 2009, 17, 1437–1444.

95. Navarro, M.; Cisneros-Fajardo, E.J.; Lehmann, T.; Sánchez-Delgado, R.A.; Atencio, R.; Silva, P.; Lira, R.; Urbina, J.A. Toward a novel metal-based chemotherapy against tropical diseases. 6. Synthesis and characterization of new copper(II) and gold(I) clotrimazole and ketoconazole complexes and evaluation of their activity against *Trypanosoma cruzi*. *Inorg. Chem.* 2001, 40, 6879–6884.

96. Sánchez-Delgado, R.A.; Lazardi, K.; Rincón, L.; Urbina, J.A. Toward a novel metal-based chemotherapy against tropical diseases. 1. Enhancement of the efficacy of clotrimazole against *Trypanosoma cruzi* by complexation to ruthenium in RuCl₂(clotrimazole)₂. *J. Med. Chem.* 1993, 36, 2041–2043.

97. Urquiola, C.; Vieites, M.; Aguirre, G.; Marin, A.; Solano, B.; Arrambide, G.; Noblia, P.; Lavaggi, M.L.; Torre, M.H.; González, M.; Monge, A.; Gambino, D.; Cerecetto, H Improving anti-trypanosomal activity of 3-aminoquinoxaline-2-carbonitrile N₁,N₄-dioxide derivatives by complexation with vanadium. *Bioorg. Med. Chem.* 2006, 14, 5503–5509.

98. Vieites, M.; Otero, L.; Santos, D.; Toloza, J.; Figueroa, R.; Norambuena, E.; Olea-Azar, C.; Aguirre, G.; Cerecetto, H.; González, M.; Morello, A.; Maya, J.D.; Garat, B.; Gambino, D. Platinum(II) metal complexes as potential anti-*Trypanosoma cruzi* agents. *J. Inorg. Biochem.* 2008, 102, 1033–43.

99. Vieites, M.; Smircich, P.; Parajón-Costa, B.; Rodríguez, J.; Galaz, V.; Olea-Azar, C.; Otero, L.; Aguirre, G.; Cerecetto, H.; González, M.; Gómez-Barrio, A.; Garat, B.; Gambino, D. Potent *in vitro* anti-*Trypanosoma cruzi* activity of pyridine-2-thiol N-oxide metal complexes having an inhibitory effect on parasite-specific fumarate reductase. *J. Biol. Inorg. Chem.* 2008, 13, 723–735.

100. Vieites, M.; Otero, L.; Santos, D.; Olea-Azar, C.; Norambuena, E.; Aguirre, G.; Cerecetto, H.; González, M.; Kemmerling, U.; Morello, A.; Maya, D.J.; Gambino, D. Platinum-based complexes of bioactive 3-(5-nitrofuryl)acroleine thiosemicarbazones showing anti-*Trypanosoma cruzi* activity. *J. Inorg. Biochem.* 2009, 103, 411–418.

101. Pagano, M.; Demoro, B.; Toloza, J.; Boiani, L.; González, M.; Cerecetto, H.; Olea-Azar, C.; Norambuena, E.; Gambino, D.; Otero, L. Effect of ruthenium complexation on trypanocidal activity of 5-nitrofuryl containing thiosemicarbazones. *Eur. J. Med. Chem.* 2009, 44, 4937-4943.
102. Donnici, C.L.; Araújo, M.H.; Oliveira, H.S.; Magalhães Moreira, D.R.; Alves Pereira, V.R.; de Assis Souza, M.; Accioly Brelaz de Castro, M.C.; Lima Leite, A.C. Ruthenium complexes endowed with potent anti-\textit{Trypanosoma cruzi} activity: Synthesis, biological characterization and structure–activity relationships. \textit{Bioorg. Med. Chem.} \textbf{2009}, \textit{17}, 5038–5043.

103. Pérez-Rebolledo, A.; Teixeira, L.R.; Batista, A.A.; Mangrich, A.S.; Aguirre, G.; Cerecetto, H.; González, M.; Hernández, P.; Ferreira, A.M.; Speziali, N.L.; Beraldo, H. 4-Nitroacetophenone-derived thiosemicarbazone rhenium and ruthenium complexes as anti-trypanosomal activity: Synthesis, biological characterization and structure–activity relationships. \textit{Bioorg. Med. Chem.} \textbf{2009}, \textit{17}, 5038–5043.

104. Otero, L.; Aguirre, G.; Boiani, L.; Denicola, A.; Rigol, C.; Olea-Azar, C.; Maya, J.D.; Morello, A.; González, M.; Gambino, D.; Cerecetto, H. Nitrofurylesemicarbazone rhenium and ruthenium complexes as anti-trypanosomal agents. \textit{Eur. J. Med. Chem.} \textbf{2006}, \textit{41}, 1231–1239.

105. Otero, L.; Vieites, M.; Boiani, L.; Denicola, A.; Rigol, C.; Opazo, L.; Olea-Azar, C.; Maya, J.D.; Morello, A.; Krauth-Siegel, R.L.; et al. Novel antitrypanosomal agents based on palladium nitrofurylesemicarbazone complexes: DNA and redox metabolism as potential therapeutic targets. \textit{J. Med. Chem.} \textbf{2006}, \textit{49}, 3322–3331.

106. Otero, L.; Smircich, P.; Vieites, M.; Ciganda, M.; Severino, P.C.; Terenzi, H.; Cerecetto, H.; Gambino, D.; Garat, B. DNA conformational changes and cleavage by ruthenium(II) nitrofurylesemicarbazone complexes. \textit{J. Inorg. Biochem.} \textbf{2007}, \textit{101}, 74–79.

107. Pereira, D.G.; De Castro, S.L.; Duran, N. Activity of \textit{N,N-}dimethyl-2-propen-1-amine derivatives in mice experimentally infected with \textit{Trypanosoma cruzi. Acta Trop.} \textbf{1998}, \textit{69}, 205–211.

108. Oliveira, D.A.; Pereira, D.G.; Fernandes, A.M.A.P.; De Castro, S.L.; Souza Brito, A.R.M.; De Souza, A.O.; Duran, N. Trypanocidal activity of 2-propen-1-amine derivatives on trypomastigotes culture and in animal model. \textit{Parasitol. Res.} \textbf{2005}, \textit{95}, 161–166.

109. De Souza, E.M.; Melo, G.; Boykin, D.W.; Wilson, W.D.; Hu, Q.; Soeiro, M.N.C. Tripanocidal activity of the phenyl-substituted analogue of furamidine DB569 against \textit{Trypanosoma cruzi} infection in vivo. \textit{J. Antimicrob. Chemother.} \textbf{2006}, \textit{58}, 610–614.

110. De Souza, E.M.; Oliveira, G.M.; Soeiro, M.N.C. Electrocardiographic findings in acutely and chronically \textit{Trypanosoma cruzi}-infected mice treated by a phenyl-substituted analogue of furamidine DB569. \textit{Drug Targets Insights} \textbf{2007}, \textit{2}, 61–69.

111. Silva, C.F.; Batista, M.M.; Batista, D.G.; de Souza, E.M.; Silva, P.B.; Oliveira, G.M.; Batista, M.M.; Shareef, A.R.; Boykin, D.W.; Soeiro, M.N.C. \textit{In vitro} and \textit{in vivo} studies of the trypanocidal activity of a diarylthiophene diamidine against \textit{Trypanosoma cruzi}. \textit{Antimicrob. Agents Chemother.} \textbf{2008}, \textit{52}, 3307–3314.

112. Silva, J.J.N.; Osakabe, A.L.; Pavanelli, W.R.; Silva, J.S.; Franco, D.W. \textit{In vitro} and \textit{in vivo} antiproliferative and trypanocidal activities of ruthenium NO donors. \textit{British J. Pharmacol.} \textbf{2007}, \textit{152}, 112–121.

113. Silva, J.J.N.; Pavanelli, W.R.; Salazar Gutierrez, F.R.; Chagas Alves Lima, F.; Ferreira da Silva, A.B.; Silva, J.S.; Franco, W.R. Complexation of the anti-\textit{Trypanosoma cruzi} drug Benznidazole improves solubility and efficacy. \textit{J. Med. Chem.} \textbf{2008}, \textit{51}, 4104–4114.

114. Shanmugasundaram, M.; Garcia-Martinez, I.; Li, Q.; Estrada, A.; Martinez, N.E.; Martinez, L.E. Microwave-assisted solidphase Dötz benzannulation reactions: A facile synthesis of 2,3-disubstituted-1,4 naphthoquinones. \textit{Tetrahedron Lett.} \textbf{2005}, \textit{46}, 7545–7548.
115. Ramos, E.I.; Garza, K.M.; Krauth-Siegel, R.L.; Bader, J.; Martinez, L.E.; Maldonado, R.A. 2,3-Diphenyl-1,4-naphthoquinone: A potential chemotherapeutic agent against Trypanosoma cruzi. J. Parasitol. 2009, 95, 461–466.

116. Engel, J.C.; Doyle, P.S.; Hsieh, I.; McKerrow, J.H. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med. 1998, 188, 725–734.

117. Barr, S.C.; Warner, K.L.; Kornreic, B.G.; Piscitelli, J.; Wolfe, A.; Benet, L.; McKerrow, J.H. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob. Agents Chemother. 2005, 49, 5160–5161.

118. Doyle, P.S.; Zhou, Y.M.; Engel, J.C.; McKerrow, J.H. Cysteine protease inhibitor cures Chagas disease in an immunodeficient-mouse model of infection. Antimicrob. Agents Chemother. 2007, 51, 3932–3939.

119. Abdulla, M.H.; Lim, K.C. Sajid, M.; McKerrow, J.H.; Caffrey, C.R. Schistosomiasis Mansoni: Novel chemotherapy using a cysteine protease inhibitor. PLoS Medicine 2007, 4, e14.

120. Urbina, J.A.; Docampo, R. Specific chemotherapy of Chagas disease: Controversies and advances. Trends Parasitol. 2003, 19, 495-501.

121. Urbina, J.A.; Payares, G.; Molina, J.; Sanoja, C.; Liendo, A.; Lazardi, K.; Piras, M.M.; Piras, R.; Perez, N.; Wincker, P.; Ryley, J.F. Cure of short- and long-term experimental Chagas’ disease using D0870. Science 1996, 273, 969–971.

122. Urbina, J.A.; Payares, G.; Sanoja, C.; Lira, R.; Romanha, A.J. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Intern. J. Antimicrob. Agents 2003, 21, 27–38.

123. Urbina, J.A.; Payares, G.; Sanoja, C.; Molina, J.; Lira, R.; Brener, Z.; Romanha, A.J. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug resistant Trypanosoma cruzi strains. Int. J. Antimicrob. Agents 2003, 21, 39–48.

124. Corrales, M.; Cardozo, R.; Segura, M.A.; Urbina, J.A.; Basombrio, M.A. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas’ disease. Antimicrob. Agents Chemother. 2005, 49, 1556–1560.

125. Silva, D.T.; de Meirelles, M.N.; Almeida, D.; Urbina, J.A.; Pereira, M.C. Cytoskeleton reassembly in cardiomyocytes infected by Trypanosoma cruzi is triggered by treatment with ergosterol biosynthesis inhibitors. Int. J. Antimicrob. Agents 2006, 27, 530–537.

126. Ferraz, M.L.; Gazzinelli, R.T.; Alves, R.O.; Urbina, J.A.; Romanha, A.J. The anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas’ disease is less dependent on gamma interferon than that of benznidazole. Antimicrob. Agents Chemother. 2007, 51, 1359–1364.

127. Ferraz, M.L.; Gazzinelli, R.T.; Alves, R.O.; Urbina, J.A.; Romanha, A.J. Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. Antimicrob. Agents Chemother. 2009, 53, 174–179.
128. Rachel, C.; Sudhakar, P.; Mark, L.; Josephine, L.; Vijay, B. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. *Antimicrob. Agents Chemother.* **2003**, *47*, 2788–2795.

129. Pinazo, M.J.; Espinosa, G.; Gállego, M.; López-Chejade, P.; Urbina, J.A.; Gascon, J. Treatment with posaconazole of a patient with systemic lupus erythematosus and Chagas disease. *Am. J. Trop. Med. Hyg.* **2010**, in press.

130. Urbina, J.A.; Concepcion, J.L.; Caldera, A.; Payares, G.; Sanoja, C.; Otomo, T.; Hiyoshi, H. *In vitro* and *in vivo* activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against *Trypanosoma cruzi*. *Antimicrob. Agents Chemother.* **2004**, *48*, 2379–2387.

131. Cerecetto, H.; Di Maio, R.; Gonzalez, M.; Risso, M.; Sagrera, G.; Seoane, G.; Denicola, A.; Peluffo, G.; Quijano, C.; Stoppani, A.O.M.; Paulino, M.; Olea-Azar, C.; Basomboko, M.A. Synthesis and anti-trypanosomal evaluation of E-isomers of 5-nitro-2-furaldehyde and 5-nitrothiophene-2-carboxaldehyde semicarbazones. *Eur. J. Med. Chem.* **2000**, *35*, 343–350.

132. Boiani, M.; Boiani, L; Denicola, A; Torres de Ortiz, S.; Serna, E.; Vera de Bilbao, N.; Sanabria, L.; Yaluff, G.; Nakayama, H.; Rojas de Arias, A.; Vega, C.; Rolón, M.; Gómez-Barrios, A.; Cerecetto, H.; González, M. 2H-Benzimidazole 1,3-dioxide derivatives: A new family of watersoluble anti-trypanosomatid. *J. Med. Chem.* **2006**, *49*, 3215–3220.

133. Porcal, W.; Hernandez, P.; Boiani, M.; Aguirre, G.; Boiani, L.; Chidichimo, A.; Cazzulo, J.J.; Campillo, N.E.; Paez, J.A.; Castro, A.; et al. *In vivo* anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives. *J. Med. Chem.* **2007**, *50*, 6004–6015.

134. Porcal, W.; Hernandez, P.; Boiani, M.; Aguirre, G.; Boiani, L.; Chidichimo, A.; Cazzulo, J.J.; Campillo, N.E.; Paez, J.A.; Castro, A.; et al. *In vivo* studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas disease. *Eur. J. Med. Chem.* **2008**, *43*, 2229–2237.

135. Boiani, L.; Davies, C.; Arredondo, C; Porcal, W.; Merlino, A.; Gerpe, A.; Boiani, M.; Pacheco, J.P.; Basomboko, M.A.; Cerecetto, H.; Gonzalez, M. *In vitro* and *in vivo* antitrypanosomatid activity of 5-nitroindazoles. *Eur. J. Med. Chem.* **2009**, *44*, 3909–3914.

136. Pérez-Cruz, F.; Jullian, C.; Rodriguez, J.; Arán, V.J.; Olea-Azar, C. Molecular encapsulation of 5-nitroindazole derivatives in 2,6-dimethyl-β-cyclodextrin: Electrochemical and spectroscopic studies. *Bioorg. Med. Chem.* **2009**, *17*, 4604–4611.

137. Rodriguez, J.; Gerpe, A.; Aguirre, G.; Kemmerling, U.; Piro, O.E.; Arán, V.J.; Maya, J.D.; Olea-Azar, C.; González, M.; Cerecetto, H. Study of 5-nitroindazoles' anti-*Trypanosoma cruzi* mode of action: Electrochemical behaviour and ESR spectroscopic studies. *Eur. J. Med. C hem.* **2009**, *44*, 1545–1553.

138. Porcal, W.; Merlino, A.; Boiani, M.; Gerpe, A; Gonzalez, M.; Cerecetto, H. Arylethenylbenzofuroxan derivatives as drugs for Chagas disease: Multigram batch synthesis using a Wittig-Boden process. *Org. Proc. Res. Dev.* **2008**, *12*, 156–162.
140. Gerpe, A.; Merlino, A.; Boiani, M.; Porcal, W.; Fagiolino, P.; Gonzalez, M.; Cerecetto, H. Development of a HPLC method for the determination of antichagasic phenylethenylbenzofuroxans and its major synthetic secondary products in the chemical production processes. *J. Pharm. Biomed. Anal.* **2008**, *47*, 88–94.

141. Boiani, M.; Merlino, A.; Gerpe, A.; Porcal, W.; Croce, F.; Depaula, S.; Rodriguez, A.; Cerecetto, H.; Gonzalez, M. o-Nitroanilines as major metabolic products of anti-*Trypanosoma cruzi* 5-phenylethenylbenzofuroxans in microsomal and cytosolic fractions of rat hepatocytes and in whole parasitic cells. *Xenobiotica* **2009**, *39*, 236–248.

142. Cabrera, M.; Lavaggi, M.L.; Hernandez, P.; Merlino, A.; Gerpe, A.; Porcal, W.; Boiani, M.; Ferreira, A.; Monge, A.; Lopez de Cerain, A.; Gonzalez, M.; Cerecetto, H. Cytotoxic, mutagenic and genotoxic effects of new anti-*T. cruzi* 5-phenylethenylbenzofuroxans. Contribution of phase I metabolites on the mutagenicity induction. *Toxicol. Lett.* **2009**, *190*, 140–149.

143. Martins, F.T.; Ayala, A.P.; Porcal, W.; Cerecetto, H.; Gonzalez, M.; Ellena, J. Structural relationships in the solid state of the anti-chagas agent (*E*)-phenylethenylbenzofuroxan. *Mol. Divers.* **2009**, doi 10.1007/s11030-009-9202-4.

144. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Deliv. Rev.* **1997**, *23*, 3–25.

145. Veber, D.F.; Johnson, S.R.; Cheng, H.Y.; Smith, B.R.; Ward, K.W.; Kopple, K.D. Molecular properties that influence the oral bioavailability of drug candidates. *J. Med. Chem.* **2002**, *45*, 2615–2623.

146. Cramer, G.M.; Ford, R.A.; Hall, R.L. Estimation of toxic hazard – A decision tree approach. *J. Cosmet. Toxicol.* **1978**, *16*, 255–276.

147. Benigni, R.; Bossa, C.; Netzeva, T.; Rodomonte, A.; Tsakovska, I. Mechanistic QSAR of aromatic amines: New models for discriminating between mutagens and nonmutagens, and validation of models for carcinogens. *Environ. Mol. Mutag.* **2007**, *48*, 754–771.

148. Chung, M.C.; Gonçalves, M.F.; Colli, W.; Ferreira, E.I.; Miranda, M.T. Synthesis and *in vitro* evaluation of potential antichagasic dipeptide prodrugs of primaquine. *J. Pharm. Sci.* **1997**, *86*, 1127–1131.  
149. Chung, M.C.; Güido, R.V.; Martinelli, T.F.; Gonçalves, M.F.; Polli, M.C.; Botelho, K.C.; Varanda, E.A.; Colli, W.; Miranda, M.T.; Ferreira, E.I. Synthesis and *in vitro* evaluation of potential antichagasic hydroxymethylnitrofurazone (NFOH-121): A new nitrofurazone prodrug. *Bioorg. Med. Chem.* **2003**, *11*, 4779–4783.  
150. Aguirre, G.; Cabrera, E.; Cerecetto, H.; Di Maio, R.; González, M.; Seoane, G.; Duffaut, A.; Denicola, A.; Gil, M.J.; Martínez-Merino, V. Design, synthesis and biological evaluation of new potent 5-nitrofuryl derivatives as anti-*Trypanosoma cruzi* agents. Studies of trypanothione binding site of trypanothione reductase as target for rational design. *Eur. J. Med. Chem.* **2004**, *39*, 421–431.

© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).